vs
ANI PHARMACEUTICALS INC（ANIP）とFIRST ADVANTAGE CORP（FA）の財務データ比較。上の社名をクリックして会社を切り替えられます
FIRST ADVANTAGE CORPの直近四半期売上が大きい（$420.0M vs $247.1M、ANI PHARMACEUTICALS INCの約1.7倍）。ANI PHARMACEUTICALS INCの純利益率が高く（11.1% vs 0.8%、差は10.3%）。FIRST ADVANTAGE CORPの前年同期比売上増加率が高い（36.8% vs 29.6%）。FIRST ADVANTAGE CORPの直近四半期フリーキャッシュフローが多い（$62.2M vs $29.1M）。過去8四半期でFIRST ADVANTAGE CORPの売上複合成長率が高い（57.5% vs 34.1%）
ANIファーマシューティカルズは米国に本社を置く特殊製薬会社で、後発医薬品とブランド処方薬の研究開発・製造・販売を行っています。主力製品分野は皮膚科、腫瘍、中枢神経系治療、感染症対策で、主に米国内の医療機関、調剤薬局、患者を対象としています。
ファーストアドバンテージコーポレーションは、世界有数の労働力スクリーニング・身元調査ソリューションプロバイダーです。テクノロジー、医療、金融、小売、製造など多様な業種の企業にサービスを提供し、雇用リスクの低減、コンプライアンス遵守、安全な職場づくりを支援しています。
ANIP vs FA — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $247.1M | $420.0M |
| 純利益 | $27.5M | $3.5M |
| 粗利率 | — | — |
| 営業利益率 | 14.1% | 10.7% |
| 純利益率 | 11.1% | 0.8% |
| 売上前年比 | 29.6% | 36.8% |
| 純利益前年比 | 367.5% | 103.5% |
| EPS（希薄化後） | $1.14 | $0.03 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $247.1M | $420.0M | ||
| Q3 25 | $227.8M | $409.2M | ||
| Q2 25 | $211.4M | $390.6M | ||
| Q1 25 | $197.1M | $354.6M | ||
| Q4 24 | $190.6M | $307.1M | ||
| Q3 24 | $148.3M | $199.1M | ||
| Q2 24 | $138.0M | $184.5M | ||
| Q1 24 | $137.4M | $169.4M |
| Q4 25 | $27.5M | $3.5M | ||
| Q3 25 | $26.6M | $2.6M | ||
| Q2 25 | $8.5M | $308.0K | ||
| Q1 25 | $15.7M | $-41.2M | ||
| Q4 24 | $-10.3M | $-100.4M | ||
| Q3 24 | $-24.2M | $-8.9M | ||
| Q2 24 | $-2.3M | $1.9M | ||
| Q1 24 | $18.2M | $-2.9M |
| Q4 25 | 14.1% | 10.7% | ||
| Q3 25 | 15.9% | 10.3% | ||
| Q2 25 | 6.6% | 9.7% | ||
| Q1 25 | 13.3% | 2.1% | ||
| Q4 24 | -2.3% | -26.3% | ||
| Q3 24 | -13.8% | 4.6% | ||
| Q2 24 | 3.7% | 5.4% | ||
| Q1 24 | 14.8% | -0.4% |
| Q4 25 | 11.1% | 0.8% | ||
| Q3 25 | 11.7% | 0.6% | ||
| Q2 25 | 4.0% | 0.1% | ||
| Q1 25 | 8.0% | -11.6% | ||
| Q4 24 | -5.4% | -32.7% | ||
| Q3 24 | -16.3% | -4.4% | ||
| Q2 24 | -1.7% | 1.0% | ||
| Q1 24 | 13.2% | -1.7% |
| Q4 25 | $1.14 | $0.03 | ||
| Q3 25 | $1.13 | $0.01 | ||
| Q2 25 | $0.36 | $0.00 | ||
| Q1 25 | $0.69 | $-0.24 | ||
| Q4 24 | $-0.45 | $-0.67 | ||
| Q3 24 | $-1.27 | $-0.06 | ||
| Q2 24 | $-0.14 | $0.01 | ||
| Q1 24 | $0.82 | $-0.02 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $285.6M | $240.0M |
| 総負債低いほど良い | — | $2.1B |
| 株主資本純資産 | $540.7M | $1.3B |
| 総資産 | $1.4B | $3.8B |
| 負債/資本比率低いほどレバレッジが低い | — | 1.61× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $285.6M | $240.0M | ||
| Q3 25 | $262.6M | $216.8M | ||
| Q2 25 | $217.8M | $184.3M | ||
| Q1 25 | $149.8M | $172.0M | ||
| Q4 24 | $144.9M | $168.7M | ||
| Q3 24 | $145.0M | $307.4M | ||
| Q2 24 | $240.1M | $269.6M | ||
| Q1 24 | $228.6M | $246.0M |
| Q4 25 | — | $2.1B | ||
| Q3 25 | — | $2.1B | ||
| Q2 25 | — | $2.1B | ||
| Q1 25 | — | $2.2B | ||
| Q4 24 | — | $2.2B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $540.7M | $1.3B | ||
| Q3 25 | $505.8M | $1.3B | ||
| Q2 25 | $436.8M | $1.3B | ||
| Q1 25 | $418.6M | $1.3B | ||
| Q4 24 | $403.7M | $1.3B | ||
| Q3 24 | $405.9M | $920.7M | ||
| Q2 24 | $455.8M | $913.3M | ||
| Q1 24 | $452.0M | $907.7M |
| Q4 25 | $1.4B | $3.8B | ||
| Q3 25 | $1.4B | $3.9B | ||
| Q2 25 | $1.3B | $3.9B | ||
| Q1 25 | $1.3B | $3.9B | ||
| Q4 24 | $1.3B | $3.9B | ||
| Q3 24 | $1.3B | $1.7B | ||
| Q2 24 | $920.8M | $1.6B | ||
| Q1 24 | $914.5M | $1.6B |
| Q4 25 | — | 1.61× | ||
| Q3 25 | — | 1.64× | ||
| Q2 25 | — | 1.65× | ||
| Q1 25 | — | 1.69× | ||
| Q4 24 | — | 1.66× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $30.4M | $65.9M |
| フリーキャッシュフロー営業CF - 設備投資 | $29.1M | $62.2M |
| FCFマージンFCF / 売上 | 11.8% | 14.8% |
| 設備投資強度設備投資 / 売上 | 0.5% | 0.9% |
| キャッシュ転換率営業CF / 純利益 | 1.10× | 19.01× |
| 直近12ヶ月FCF直近4四半期 | $171.4M | $188.5M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $30.4M | $65.9M | ||
| Q3 25 | $44.1M | $72.4M | ||
| Q2 25 | $75.8M | $37.3M | ||
| Q1 25 | $35.0M | $19.5M | ||
| Q4 24 | $15.9M | $-85.7M | ||
| Q3 24 | $12.5M | $43.5M | ||
| Q2 24 | $17.4M | $32.0M | ||
| Q1 24 | $18.3M | $38.3M |
| Q4 25 | $29.1M | $62.2M | ||
| Q3 25 | $38.0M | $71.2M | ||
| Q2 25 | $71.8M | $36.1M | ||
| Q1 25 | $32.5M | $19.0M | ||
| Q4 24 | $13.5M | $-86.0M | ||
| Q3 24 | $7.7M | $43.1M | ||
| Q2 24 | $13.0M | $31.4M | ||
| Q1 24 | $13.7M | $38.0M |
| Q4 25 | 11.8% | 14.8% | ||
| Q3 25 | 16.7% | 17.4% | ||
| Q2 25 | 34.0% | 9.2% | ||
| Q1 25 | 16.5% | 5.4% | ||
| Q4 24 | 7.1% | -28.0% | ||
| Q3 24 | 5.2% | 21.6% | ||
| Q2 24 | 9.4% | 17.0% | ||
| Q1 24 | 10.0% | 22.4% |
| Q4 25 | 0.5% | 0.9% | ||
| Q3 25 | 2.7% | 0.3% | ||
| Q2 25 | 1.9% | 0.3% | ||
| Q1 25 | 1.3% | 0.1% | ||
| Q4 24 | 1.3% | 0.1% | ||
| Q3 24 | 3.2% | 0.2% | ||
| Q2 24 | 3.2% | 0.4% | ||
| Q1 24 | 3.3% | 0.2% |
| Q4 25 | 1.10× | 19.01× | ||
| Q3 25 | 1.66× | 27.91× | ||
| Q2 25 | 8.87× | 121.25× | ||
| Q1 25 | 2.23× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 17.22× | ||
| Q1 24 | 1.00× | — |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
FA
| First Advantage Americas | $209.9M | 50% |
| Sterling | $185.9M | 44% |
| First Advantage International | $24.2M | 6% |
